improve understanding of risk factor control and mortality in persons with type 1 diabetes. To achieve this, we studied mortality rates in patients without coexisting renal complications, who did not smoke and had optimal glycemic control in relation to matched controls from the general population. We also identified risk factors for death due to ketoacidosis or hypoglycemia in younger adults with type 1 diabetes.
Methods

Participants
The study design and baseline characteristics of the cohort have been described elsewhere. 5 In brief, individuals with type 1 diabetes from the Swedish National Diabetes Register (NDR) were included. Type 1 diabetes was defined based on epidemiologic data as treatment with insulin and diagnosis before age 30. 5, 6 Patients with at least 1 listing in the NDR between January 1, 1998, and December 31, 2011, were included. For every patient record, 5 controls matched on age, sex, and county were randomly selected from the general population. A flow-chart for selection of persons included in the cohort is shown in Figure 1 . The final cohort included 33 915 study subjects and 169 249 controls. Subjects and controls were followed from baseline until death or December 31, 2011.
Procedure
Information on coexisting medical conditions and causes of death were retrieved by linking personal identification numbers from patients and controls to the Swedish Inpatient Registry and Cause of Death Registry. 5 Information on education and country of birth was retrieved from the Longitudinal Integration Database for Health Insurance and Labor Market Studies. 5, 7, 8 Information on hemoglobin A1c (HbA1c), diabetes duration, smoking, microalbuminuria, and creatinine level were retrieved from NDR. Updated mean HbA1c was used, which is the mean of HbA1c levels until a certain time point, for example, if 3 HbA1c-values exist, it is the mean of these 3 values. 9 In Sweden, HbA1c values are measured in accordance with the International Federation of Clinical Chemistry (IFCC) standard. 10 Categories of HbA1c were predefined into the general targets of HbA1c and categories of 10 mmol/ mol (approximately 1 percentage unit) of HbA1c: less than or equal to 52 mmol/mol (≤6.9%), 53-62 mmol/mol (7.0-7.8%), 63-72 mmol/mol (7.9-8.7%), 73-83 mmol/mol (8.8-9.7%), and ≥83 mmol/mol ( ≥ 9.7%).
Two renal variables 5 were evaluated:
1. Normoalbuminuria, microalbuminuria, macroal buminuria, or chronic kidney disease (CKD) stage 5 (defined as renal dialysis, transplantation, or eGFR<15 ml/min) 2. Estimated glomerular filtration rate (eGFR) ≥ 60 ml/ min, <60 ml/min, or stage 5 CKD Microalbuminuria was defined as 2 positive results for 3 urine samples obtained within 1 year, with positivity defined as an albumin:creatinine ratio of 3 to 30 mg per millimole (approximately 30 to 300 mg per gram) or a urinary albumin clearance of 20 to 200 μg per minute (20 to 300 mg per liter). Macroalbuminuria was defined as an albumin:creatinine ratio of more than 30 mg per millimole (close to 300 or more mg per gram) or a urinary albumin clearance of more than 200 μg per minute (>300 mg per liter). The Modification of Diet in Renal Disease formula was used to calculate eGFR. 11 All-cause and cardiovascular disease (CVD) mortality were evaluated in T1D patients and controls in relation to the 2 renal variables and coexisting updated mean HbA1c levels. The influence of smoking was then added to evaluate excess risk of mortality. Smokers were defined as patients smoking ≥1 cigarette a day or who quit smoking less than 3 months earlier. Smoking status is a variable in the NDR and was categorized into smoking and non-smoking.
To identify predictors of death due to ketoacidosis or hypoglycemia in persons <50 years, we evaluated age, sex, smoking, diabetes duration, education level, born in Sweden or other country, BMI, updated mean HbA1c, insulin delivery type (insulin pump versus multiple daily insulin injections), earlier hypoglycemia or ketoacidosis, renal complications (normo-versus non-normoalbuminuria), eGFR level (CKD stage 1-5), and previous intoxication events. (See the online supplementary material for ICD codes used.)
The study was approved by the ethical committee at the University of Gothenburg (Gothenburg, Sweden).
Statistics
Cox regression was used to evaluate the excess risk of coexisting risk factors on all-cause and CVD mortality, with timeupdated mean HbA1c categories and either normoalbuminuria and eGFR ≥ 60 or non-normoalbuminuria or eGFR <60 ml/ min as main effect variable. Four models were investigated: model 1 was stratified in matched groups according to age, sex, and county; model 2 was adjusted for time-updated age and sex; model 3 was also stratified for diabetes duration at baseline; model 4 was also adjusted for birth in Sweden or elsewhere, level of education, and prebaseline history of conditions other than diabetes (ie, coronary heart disease, atrial fibrillation, heart failure, acute myocardial infarction, stroke, or cancer). A similar methodology was used for a subgroup of patients that were nonsmokers at baseline. Cox regression was also used in the prediction analyses of death due to ketoacidosis or hypoglycemia. The proportional hazards assumption was fulfilled. All tests were 2-tailed and conducted at the .05 significance level. All analyses were performed by using SAS version 9.4 (SAS Institute).
Results
Baseline characteristics of the cohort consisting of 33 915 subjects and 169 249 controls are shown in Table 1 . Mean age was 35.8 and 35.7 years and mean follow-up was 8.0 and 8.3 years, respectively. In persons with diabetes mean HbA1c was 8.2% (65.8 mmol/mol), mean diabetes duration was 20.4 years, and 13.6% were smokers. Number of subjects who died from any cause of mortality was 2701 (8.0%) in the diabetes group and 4835 (2.9%) in the control group, and for CVD mortality the figures were 927 (2.7%) and 1444 (0.9%) respectively. In total, 34% (927/2701) of the deaths in the patient cohort were attributed to CVD. Table 2 shows hazard ratios (HRs) for all-cause and cardiovascular disease (CVD) mortality in persons with type 1 diabetes, normoalbuminuria, and coexisting eGFR ≥ 60 ml/min by various updated mean HbA1c-levels compared to matched controls. HRs in the fully adjusted model for persons with type 1 diabetes and HbA1c ≤ 52 mmol/mol (6.9%) versus controls were 1.22 (95% CI 0.98-1.52) and 1.03 (95% CI 0.66-1.60), respectively, increasing monotonically with higher updated mean HbA1c. For nonsmoking persons with type 1 diabetes the HRs for all-cause and CVD mortality were slightly lower in the fully adjusted model: 1.11 (95% CI 0.87-1.42) and 0.89 (95% CI 0.53-1.48), respectively, for those with updated mean HbA1c ≤ 52 mmol/mol (6.9%) ( Table 3) .
The HRs for all-cause and CVD mortality for subjects were generally somewhat higher when only 1 renal variable (normoalbuminuria or eGFR ≥ 60 ml/min) was evaluated separately for various updated mean HbA1c levels (Supplemental Tables S1 and S2).
In total, 78% of patients and 52.9% of patient-years belonged to the category of normoalbuminuria + eGFR ≥ 60 ml/min during the study period. Corresponding figures for nonsmokers at baseline belonging to these categories were 63.9% and 44.3%. There were 18.5% of patients and 10.0% of patient-years belonging to the category of updated mean HbA1c ≤ 52 mmol/mol (6.9%), normoalbuminuria, and eGFR ≥ 60 ml/min. In addition, there were 16.0% of persons and 8.8% of patient-years belonging to these categories evaluated in persons with a nonsmoking status at baseline.
The number of patients with diabetes younger than 50 years that have died due to hypoglycemia or ketoacidosis was 81 (3% of all deaths). Univariable and multivariable predictors of death due to hypoglycemia or ketoacidosis in subjects younger than 50 years are shown in Table 4 .
Discussion
In this nationwide study of individuals in Sweden, nonsmoking type 1 diabetic patients with HbA1c <52 mmol/mol (6.9%) without renal complications had no excess risk of mortality compared to that of the general population. Another key finding was the identification of several predictors for death due to hypoglycemia or ketoacidosis in adults with type 1 diabetes younger than age 50, namely male sex, current smoking, lower educational level, presence of microalbuminuria, or more advanced renal complications, earlier hospital diagnosis of hypoglycemia or ketoacidosis, and earlier hospital diagnosis of intoxication.
Strengths of the current study include that all persons with type 1 diabetes in Sweden, in principle, are included in the NDR, which also includes good coverage of risk factors. 5 A limitation is that information on several mortality risk factors was not available in controls. However, in contrast to many other studies using general life tables for controls, information on coexisting diseases, educational level, and birth in Sweden existed in both patients and matched controls. Furthermore, although the point estimates for hazard of allcause and CVD death in nonsmoking persons without renal complications and on-target HbA1c were close to 1 in several models, the confidence intervals were relatively wide, with an upper limit of 1.4-1.5 for all-cause and CVD death respectively. However, these limits are lower than in earlier studies examining risk factors separately. 4, 5 Furthermore, our findings are strengthened by the fact that consistent patterns were seen between higher updated mean HbA1c and mortality in persons without renal complications. It should be noted that residual confounding cannot be excluded due to the observational nature of the study.
Our results indicate that obtaining good glycemic control early after diagnosis of type 1 diabetes and onward may lead to considerable reductions in excess mortality. Since hyperglycemia is a prerequisite for diabetic nephropathy, 12 it may be possible to avoid a major risk factor for mortality in many cases. Furthermore, most persons with type 1 diabetes today are free from renal complications, but most do not reach HbA1c targets (approximately 20% do in Sweden). The current findings suggest that substantially increasing this proportion, especially before renal complications appear, could lead to a reduction in the excess risk of mortality in this patient group.
Moreover, it is possible that more aggressive smoking cessation programs could further reduce the excess risk of mortality to levels comparable to the general population. Since persons with type 1 diabetes generally have frequent contact with care providers, special smoking cessation programs, in line with those generally existing for persons with cardiovascular disease, should be considered.
Earlier studies are sparse of excess mortality in persons with type 1 diabetes who target goals for HbA1c, are free of renal complications and avoid smoking. This is also the case regarding evaluations of patient characteristics for patients dying due to acute complications. One reason is likely that very large patient cohorts are needed over long time periods including information of risk factors on an individual level and such patient cohorts are generally sparse. In the current cohort of 33 915 persons with type 1 diabetes there were 81 deaths due to ketoacidosis or hypoglycemia in patients less than 50 years of age. In a patient cohort being considerably smaller it would be difficult to evaluate patient characteristics. Regarding excess mortality in relation to risk factor control, the confidence intervals were relatively wide in spite of the large patient cohort, also illustrating the need of a large patient cohort. However, it should be noted that there are other cohort studies showing that acute complications are major causes of deaths in younger persons with type 1 diabetes, although not generally evaluating predictors of these deaths. [13] [14] [15] [16] A limitation of the Swedish Cause of Death Register using International Classification of Disease (ICD) codes is that it is generally not possible to determine whether deaths have occurred due to hypoglycemia or ketoacidosis (ICD-10 codes E10.0, E11.0, E14.0, E10.1, E11.1, E14.1). This has also been the case in earlier registry studies of deaths due to acute complications. 5, 16 However, the characteristics associated with these deaths, although it must be interpreted with great caution, indicate that ketoacidosis is likely a more common cause than hypoglycemia. The patients had generally higher HbA1c than average in persons with type 1 diabetes and renal complications were more common, also indicating a history of pronounced hyperglycemia in these patients. Noteworthy, there were no differences found regarding deaths due to acute complications in younger adults for persons treated with insulin pump compared to multiple daily insulin injections.
Conclusion
In conclusion, our findings suggest that the rates of mortality in persons with type 1 diabetes may converge with those of the general population by reaching HbA1c targets, and avoiding renal complications and smoking. Clinicians should also pay attention to certain patient groups, particularly young adults with type 1 diabetes, who are at risk of death due to hypoglycemia and ketoacidosis as elucidated here.
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